The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
JAK inhibitors and emerging therapies for MDS/MPN overlap syndromes
Abdulraheem Yacoub, MD, The University of Kansas Cancer Center, Kansas City, MO, discusses the role of JAK inhibitors and emerging treatment strategies for patients with myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Dr Yacoub highlights clinical findings with ruxolitinib and fedratinib, particularly in patients with proliferative disease features, and explores the potential of newer JAK inhibitors and combination therapies to improve clinical outcomes. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
